Anaplastic lymphoma kinase (ALK) gene translocations are pro-tumoral driver alterations, present in 3–7% of non-squamous non-small cell lung cancer (NSCLC) with specific, clinic and histologic features. The therapeutic strategy depends on anti-ALK tyrosine kinase inhibitors (TKIs) of which crizotinib was the first approved for clinical use. Despite its use improved significantly progression-free survival, overall response rate and duration of response of this illness, after a median period of 10.9 months all patients progress due to the development of acquired resistance mutations in the ALK tyrosine kinase domain in approximately one third of patients. Moreover, 60–90% of patients treated with crizotinib has a progression in the central nervous system (CNS) in absence of extracranial worsening of the disease. This is primarily attributed to poor CNS penetration by crizotinib as many pre-clinical and clinical models suggest. For instance, in order to overtake acquired resistance to crizotinib, prolong the control of the disease and manage CNS localizations, several II and III generation TKIs have been developed. Some of them were approved after the failure of crizotinib (ceritinib, alectinib, brigatinib and lorlatinib) and in first line setting (ceritinib, alectinib and brigatinib) while others are still under evaluation for TKI-naive patients such as lorlatinib, ensartinib and entrectinib. In this review we will discuss the most recent results of new TKIs in order to describe a fast growing therapeutic landscape in this setting.

**Keywords:** Anti-anaplastic lymphoma kinase tyrosine kinase inhibitors (anti-ALK TKIs); resistance; alectinib; ceritinib; brigatinib

Submitted Aug 22, 2019. Accepted for publication Sep 18, 2019.
doi: 10.21037/tlcr.2019.09.14
View this article at: http://dx.doi.org/10.21037/tlcr.2019.09.14
alterations increase the affinity for adenosine triphosphate, inducing conformational changes with steric hindrance and interference with the downstream signaling pathway (6-11). Other mechanisms of resistance are amplification of ALK fusion gene, alone or in combination with other molecular alterations (6), or bypass pathways such as amplification of epidermal growth factor receptor (EGFR) or of insulin-like growth factor (IGF-1R) or cKIT mutation (12-14).

Among 60–90% of patients receiving crizotinib has a CNS progression which is the first site of relapse in 46% of cases without evidence of extracranial worsening (3,15-17). This is attributed to poor CNS penetration by crizotinib as it is shown by the analysis of cerebro-spinal fluid from patients progressing in the CNS (18) and reinforced by the fact that ORR (33% vs. 18%) and prolongation in the median time to intracranial progression (13 vs. 7 months) are superior when crizotinib is given after radiotherapy than when is given alone (19) suggesting that prior radiation may probably increase the blood-brain barrier (BBB) permeability improving the CNS activity of crizotinib (20).

In order to overtake acquired resistance to crizotinib, prolong the control of the disease and manage CNS localizations, several II and III generation TKIs have been developed (Table 1), entering in clinic after the failure of crizotinib (ceritinib, alectinib, brigatinib and lorlatinib) (Table 2) and in first line setting (ceritinib, alectinib and brigatinib) (Table 3) while others are still under clinical evaluation for TKI-naive patients such as lorlatinib, ensartinib and entrectinib.

In this review we will discuss the most recent results of TKIs in order to describe a fast growing therapeutic landscape in this setting.

### Alectinib (RO5424802/CH5424802, Alecensa)

Alectinib is a strong and selective, competitive with ATP, II generation TKI mainly directed against ALK and Rearranged during Transfection (RET) gene rearrangements (48). In vitro it shows a threefold increase of ALK inhibition (53 nM alectinib versus 150.8 nM crizotinib) by inducing caspase-mediated apoptosis in EML4-ALK cell lines, with a dose-dependent tumor growth inhibition (21). Its half maximal inhibitory concentration (IC50) is 1.9 nM while that of crizotinib is 3 nM (21). It is metabolized via hepatic CYP3A4 enzymes to M4, an active metabolite, and mainly excreted via the feces; mean terminal half-life is about 30 hours (49). Alectinib showed high efficacy against several crizotinib-resistant mutations in ALK, including L1196M, G1269A, C1156Y, F1174L, 1151Tins, and L1152R but not G1202R (8,21). The drug strongly penetrate the CNS, as shown in intracranial tumor implantation model where it is able to inhibit the growth of ALK-positive CNS lesions; in this model p-glycoprotein (P-gp) doesn’t transport the drug, showing a relevant CNS-to-plasma ratio (50).

Alectinib was initially evaluated in 2 phase I/II trials: in the first trial among 46 Japanese patients with ALK rearranged, untreated NSCLCs, 2 (4.3%) complete responses (CR) and 41 (89.1%) partial responses (PR) were seen with 7 having disease control for more than 6.5 months (51). The second phase I trial was conducted in US patients in crizotinib-resistant NSCLCs: objective responses (OR) were noted in 55% of patients with 2% CR, 32% PR, 20% unconfirmed PR; 36% of patients had stable disease (SD). Eleven (52%) out of 21 patients with baseline CNS metastases showed OR of which 6 (29%) CR, 5 (24%)
Delmonte et al. New generation ALK inhibitors

PR and 8 (38%) SD (52). Twenty-six per cent of patients in the Japanese trial showed treatment-related adverse events (TRAEs) grade 3–4 toxicity and 8% in the American trial, being represented by decreased neutrophil count, increased blood creatine phosphokinase, γ-glutamyl transpeptidase and hypophosphataemia (51,52).

In the crizotinib-resistant NSCLC setting, the pooled analysis of 2 phase II trials confirmed ORR of 51.3%, disease control rate (DCR) of 78.8%, mDOR of 14.9 months, mPFS of 8.3 months and median overall survival (mOS) of 26.0 months (31-33). The pooled analysis confirmed also the activity against CNS metastases with an intracranial ORR (iORR) of 64.0%, DCR 90.0% and mDOR 10.8 months iORR was 35.8% in patients with prior radiotherapy and 58.5% in those untreated (31,32,34). Most adverse events (AEs) were grade 1 to 2 (32); in 40% of patients grade 3 or higher AEs occurred, leading to treatment withdrawn or interruptions or modification in 6–33% of patients (33). The most common grade 3–4 AEs were represented by changes in laboratory values, such as increase of blood creatine phosphokinase and of transaminases (31).

In the ALUR trial superiority of alectinib versus platinum-based chemotherapy in advanced, crizotinib-resistant NSCLC was assessed by an independent review committee (IRC) in terms of PFS (7.1 vs. 1.6 months), ORR of CNS baseline lesions (54.2% vs. no responses). The treatment period was longer in the alectinib arm (20.1  

---

Table 2 II and III generation TKIs in crizotinib pre-treated patients

<table>
<thead>
<tr>
<th>Drug</th>
<th>Phase</th>
<th>ORR, %</th>
<th>mDOR, mo</th>
<th>mPFS, mo</th>
<th>iORR, %</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alectinib</td>
<td>II</td>
<td>51.3</td>
<td>14.9</td>
<td>8.3</td>
<td>64</td>
<td>(31-34)</td>
</tr>
<tr>
<td></td>
<td>III</td>
<td>–</td>
<td>20.1†</td>
<td>7.1</td>
<td>54.2</td>
<td>(35)</td>
</tr>
<tr>
<td>Ceritinib</td>
<td>I</td>
<td>56</td>
<td>–</td>
<td>6.9</td>
<td>65</td>
<td>(36)</td>
</tr>
<tr>
<td></td>
<td>II</td>
<td>38.6</td>
<td>9.7</td>
<td>5.7</td>
<td>45</td>
<td>(37)</td>
</tr>
<tr>
<td></td>
<td>III</td>
<td>–</td>
<td>–</td>
<td>5.4</td>
<td>–</td>
<td>(38)</td>
</tr>
<tr>
<td>Brigatinib</td>
<td>I/II</td>
<td>83</td>
<td>–</td>
<td>13.2</td>
<td>53†</td>
<td>(39)</td>
</tr>
<tr>
<td></td>
<td>II</td>
<td>54</td>
<td>–</td>
<td>12.9</td>
<td>67</td>
<td>(40)</td>
</tr>
<tr>
<td>Lorlatinib</td>
<td>I</td>
<td>57</td>
<td>11.7</td>
<td>9.6</td>
<td>–</td>
<td>(41)</td>
</tr>
<tr>
<td></td>
<td>II</td>
<td>47</td>
<td>NR</td>
<td>NR</td>
<td>87</td>
<td>(42)</td>
</tr>
<tr>
<td>Ensartinib</td>
<td>I/II</td>
<td>69</td>
<td>–</td>
<td>9.0</td>
<td>69</td>
<td>(43)</td>
</tr>
</tbody>
</table>

*, weeks; †, in patients with measurable intracranial lesions. TKIs, tyrosine kinase inhibitors; ORR, objective response rate; mDOR, median duration of response; mPFS, median progression-free survival; iORR, intracranial objective response rate; mo, months; Ref., reference; NR, not reached.

Table 3 Clinical trials in TKIs-naive patients

<table>
<thead>
<tr>
<th>Drug</th>
<th>Control arm</th>
<th>ORR, %</th>
<th>mPFS, mo</th>
<th>iORR, %</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alectinib</td>
<td>Crizotinib</td>
<td>92</td>
<td>10.2</td>
<td>–</td>
<td>(44)</td>
</tr>
<tr>
<td></td>
<td>Crizotinib</td>
<td>82.9</td>
<td>11.1</td>
<td>85.7*</td>
<td>71.4*</td>
</tr>
<tr>
<td>Ceritinib</td>
<td>Chemotherapy</td>
<td>72.5</td>
<td>16.6</td>
<td>8.1</td>
<td>72.7</td>
</tr>
<tr>
<td>Brigatinib</td>
<td>Crizotinib</td>
<td>71</td>
<td>67†</td>
<td>43†</td>
<td>78</td>
</tr>
<tr>
<td>Lorlatinib</td>
<td>–</td>
<td>90</td>
<td>NR</td>
<td>66.7</td>
<td>–</td>
</tr>
</tbody>
</table>

*, in patients with previous radiotherapy; †, intended as estimated 12-month progression-free survival. TKIs, tyrosine kinase inhibitors; ORR, objective response rate; Exp., experimental; mPFS, median progression-free survival; iORR, intracranial objective response rate; mo, months; Ref., reference; NR, not reached.
versus 6.0 weeks). Alectinib showed 27.1% of grade 3 AEs while chemotherapy 41.2%; treatment discontinuation due to AEs was 5.7% with alectinib and 8.8% with chemotherapy (35).

Finally alectinib was evaluated in first line in untreated patients compared crizotinib in two phase III, randomized trials. The first one, the J-ALEX study, showed in a Japanese population a PFS not reached at the moment of publication in the alectinib arm while with crizotinib PFS was 10.2 months; OR was 92% versus 79% respectively (44). The second trial, the ALEX trial performed in the Caucasian population, showed similar activity with a 12-month event-free survival rate of 68.4% with alectinib versus 48.7% with crizotinib. The hazard ratio (HR) for disease progression or death in the alectinib arm was 0.47 and the mPFS in the experimental arm not reached; OR was 82.9% with alectinib and 75.5% (P=0.09) with crizotinib (45). Investigator-assessed PFS with alectinib was similar between patients with (HR 0.40, 95% CI: 0.25–0.64) and without (HR 0.51, 95% CI: 0.33–0.80, P interaction =0.36) CNS metastases at baseline, independently to a previous radiotherapy. Time to progression of brain metastases was longer in the alectinib arm and similar patients with and without baseline CNS metastases (P=0.0001); alectinib obtained an iORR of 85.7% in patients who underwent to radiotherapy and of 78.6% in not treated CNS lesions while crizotinib an iORR of 71.4% and 40.0%, respectively (53). In the two trials grade 3-5 AEs were 41% with alectinib and 50% with crizotinib (45).

Ceritinib (LDK378, Zykdria)

Ceritinib is a potent and selective, ATP-competitive, oral TKI, directed against rearrangement of ALK and protooncogene receptor tyrosine kinase (ROS1) and alterations of insulin growth factor-1 receptor (IGF-1R). It's able to inhibit ALK with 20-fold greater potency than crizotinib in enzymatic assays with an IC50 of 0.15 nM with a more durable antitumor activity (22). Cytochrome CYP3A metabolizes ceritinib which is mainly excreted via feces (92.3% vs. 1.3% via urine) (54). Ceritinib is highly active against the most common crizotinib-resistance mutations, including L1196M, G1269A, S1206Y and I1171T (22). Finally a tissue distribution study in rats shows that ceritinib cross the blood brain barrier, with a brain-to-blood exposure ratio of approximately 15% (36).

The development of ceritinib was conducted in the ASCEND program, starting with the phase I trial conducted in TKI-naive and TKI-pretreated patients: ORR was 72.0% and 56.0%, respectively; mPFS was 18.4 and 6.9 months. Among patients with confirmed brain intracranial involvement, DCR was 79% in TKI-naive and 65% TKI-pretreated patients. The most frequent grade 3–4 AEs were increased alanine aminotransferase (30%), increased aspartate aminotransferase (10%), diarrhoea and nausea in 6% of patients (36).

The phase II (ASCEND-2) trial involved patients progressing after crizotinib and 2 or more other treatment regimens, encompassing also people with asymptomatic or neurologically stable baseline CNS metastases: ORR was 38.6%, DCR 77.1%, median time to response 1.8 months, mDOR 9.7 months and mPFS 5.7 months. Among 100 patients with baseline brain metastases, iORR was 45.0%. Adverse events were in the majority grade 1 or 2; the most frequent were nausea (81.4%), diarrhea (80.0%), and vomiting (62.9%). Improvement in quality of life was shown by patient-reported outcomes (37).

In the phase III (ASCEND-4) trial treatment-naive population was randomized to receive ceritinib or platinum-based chemotherapy: blinded IRC showed a mPFS of 16.6 months with ceritinib vs. 8.1 months with chemotherapy (HR 0.55; 95% CI: 0.42–0.73; P<0.00001). Diarrhoea (85%), nausea (69%), vomiting (62.9%) and increase in alanine aminotransferase (60%) were the most frequent AEs with ceritinib (46). Confirmation of those results were obtained in the phase III trial (ASCEND-5) in which patients at failure of chemotherapy and crizotinib were randomized to receive ceritinib or chemotherapy with mPFS of 5.4 months (95% CI: 4.1–6.9 months) in ceritinib arm and 1.6 months (1.4–2.8 months). Forty-three per cent of patients receiving ceritinib experienced serious adverse events (SAEs) vs. 32% in the chemotherapy group.

Increased alanine aminotransferase concentration (21%), increased γ glutamyltransferase concentration (21%) and increased aspartate aminotransferase concentration (14%) were the most represented grade 3–4 AEs in patients treated with ceritinib (38).

Given the high incidence of AEs, the phase Ib (ASCEND-8) trial compared in term of activity and tolerability 3 different doses of ceritinib after a light breakfast instead at fasted state showing that the smallest one, 450 mg with food, demonstrated pharmacokinetic parameters comparable to those obtained with the registrative dose, 750 mg fasted (55). The arm receiving 450 mg showed the lowest proportion of patients with dose reductions, of patients with gastrointestinal toxicities and...
the longest mDOR; ORR was similar in the 3 arms (56).

**Brigatinib (AP26113, Alunbrig)**

Brigatinib is a synthetic, oral, II generation TKI able to inhibit ALK kinase with a stronger potency than crizotinib (23), exerting dual inhibition of ALK and EGFR (epidermal growth factor receptor) (L858R) in humans (24). It shows high selectivity in inhibiting ROS1, FLT3, and mutant variants of FLT3 (D835Y) but low activity against EGFR with a T790M resistance mutation (L858R/T790M), native EGFR, IGF1R (23). Brigatinib is mainly metabolised by CYP2C8 and CYP3A4 in vitro. About 3.5% of brigatinib gets metabolised to its primary metabolite, less potent, and 92% remain unchanged. Hepatic elimination is the major route of excretion, 65% of administered dose being recovered from feces and 25% from urine (57,58). Steady state maximum concentration is reduced to be about 13% when administered after high fat meal (59). In orthotopic brain tumor model, brigatinib showed a prolongation of median survival of mice and a significant reduction of intracranial tumor burden more actively than crizotinib (23). Brigatinib displays an inhibitory profile against all 17 known resistance mutations of ALK, including the G1202R and L1196M, superior than that of crizotinib, ceritinib and alectinib (23).

Brigatinib was initially evaluated in a phase I/II trial. After a 3+3 dose escalation phase in which the dose-limiting toxicities (DLT) were increased transaminases and dyspnoea, the phase 2 part evaluated 3 oral once-daily regimens into 5 cohorts: TKI-naive NSCLC (cohort 1), crizotinib-pretreated NSCLC (cohort 2), EGFR T790M-positive NSCLC resistant to previous anti-EGFR TKI (cohort 3), solid tumors with abnormalities of the molecular pathways, targets of the drug (cohort 4) and crizotinib-naive or crizotinib-treated NSCLC with active, measurable, intracranial CNS metastases (cohort 5). Responses were seen only in NSCLCs: ORR was 100% in cohort 1, 74% in cohort 2 and 83% in cohort 5. The mPFS was not reached in crizotinib-naive patients and 13.2 months in crizotinib-pretreated patients; probability of OS at 1 year was 100% and 78%, respectively. In the cohort 5 iORR was 53% in patients with CNS measurable lesions and 35% in the non-measurable disease group. Intracranial mPFS was 15.6 months, increasing to 22.3 months for patients with no prior radiotherapy. The most active dose was represented by 180 mg daily but the occurrence of pulmonary events within the first week of treatment, higher with this dose and causing dose interruption, lead to a schedule with a 7-day lead-in dose of 90 mg daily followed by 180 mg daily continuously. Across all doses increased lipase concentration (9%), dyspnoea (6%) and hypertension (5%) were the most represented grade 3–4 TRAEs (39).

Those data were subsequently confirmed in the phase II, ALTA trial in which patients progressing to crizotinib were randomized to receive brigatinib at 90 mg daily in arm A or 180 mg daily with a 7-day lead-in at 90 mg in arm B: ORR was 45% in arm A and 54% in arm B; iORR in patients with baseline CNS target lesions 42% (11 of 26 patients) and 67% (12 of 18 patients) respectively; PFS 9.2 months and 12.9 months respectively. Common TRAEs were mainly grades 1–2 and were mainly represented by nausea, diarrhea, headache and cough (40). Given these results arm B schedule of brigatinib was compared to crizotinib in the first line setting in the phase 3 ALTA-1L trial. At the first interim analysis the rate of PFS was higher in the experimental arm with an estimated 12-month PFS of 67% compared to 43% (HR 0.49; P<0.001) in the crizotinib arm; ORR was 71% with brigatinib and 60% with crizotinib; iORR among patients with measurable lesions was 78% and 29%, respectively, without new safety data (47).

**Lorlatinib (PF-06463922, Lorviqua)**

Lorlatinib is a III generation macrocyclic, ATP-competitive, oral TKI showing potent inhibition against ALK (Ki 1/4 0.70 nM) and ROS1 rearrangement (Ki 1/4 0.025 nM) (25,26). In vitro and in vivo metabolite assays, lorlatinib was able to alter PK of concomitant drugs substrate of the CYP/CYP450 pathways, leading to the contraindication to CYP3A inhibitors since 12 days prior to the first dose of lorlatinib in clinical trials. It is active against all known resistant mutants for I and II generation ALK inhibitors including G1202R (27): in fact mean IC50 values against G1202R of lorlatinib, crizotinib, ceritinib and alectinib were 80, 560, 309, and 595 nM, respectively, permitting to conclude that only lorlatinib inhibits this target (27).

Lorlatinib was developed from crizotinib in order to facilitate the CNS penetration and to reduce the P-gp-dependent efflux (25,60). In fact BBB penetration was shown by assays in a non-human primate model while in mouse models the systemic and intracranial efficacy of lorlatinib increased the survival (61).

The drug was evaluated initially in a phase I trial encompassing patients with advanced, NSCLC of which ALK-rearranged patients, TKI-naive or progressing
after at least 1 previous TKI, represented the 76% of trial population. In this group ORR was 46% with 7% CR, 39% PR and 20% SD; ORR 57% in patients with a previous ALK TKI and 42% in those treated with 2 or more ALK TKIs. The estimated mDOR was 11.7 months for those previously treated; mPFS was 9.6 months being 13.5 months for patients treated with 1 previous TKI and 9.2 in those with 2 or more TKIs. The most common TRAEs were hypercholesterolaemia (72%), hypertriglyceridaemia (39%), peripheral neuropathy (39%) and peripheral oedema (39%) but the only DLT was grade 2 neurocognitive alterations (slowed speech, mentation, and word-finding difficulty) (41).

These data are at present under evaluation in a phase II trial involving a similar population in 6 different expansion cohorts (EXP1–6) according to previous treatments and the status of molecular drivers. Preliminary data were published concerning ALK-rearranged NSCLC cohorts encompassing patients TKI naïve (EXP1), crizotinib-pretreated without (EXP2) or with (EXP3A) previous chemotherapy, with 1 previous non-crizotinib TKI with or without chemotherapy (EXP3B) and with 2 (EXP4) or 3 (EXP5) previous TKIs with or without chemotherapy. In EXP1 OR was 90.0%; in EXP2–5 OR was 47.0% being 69.5% in EXP2–3A, 32.1% in EXP 3B and 38.7% in EXP4–5. In patients with CNS measurable lesions iORR was 66.7% in EXP1, 87.0% in EXP2–3A, 55.6% in EXP3B and 53.1% in EXP4–5. In all the expansions mDOR was not reached nor in the intracranial neither in the extracranial disease; mPFS was not reached in EXP 1 and in EXP2–3A but it was 5.5 months (in EXP3B and 6.9 months in EXP4–5. The most common TRAEs across all patients were hypercholesterolaemia (81% overall and 16% grade 3–4) and hypertriglyceridaemia (60% overall and 16% grade 3–4). Serious TRAEs occurred in 7% of patients and only 3% permanently discontinued treatment because of iatrogenic toxicity. CNS effects of any cause were reported in 39% of patients, including changes in cognitive function (23%), mood (22%) and speech (8%) and were grade 1 or 2 in severity, transient, intermittent, and reversible after dose modifications (42).

Finally the drug has been compared to crizotinib in the Phase III CROWN study (NCT03052608) of which the enrollment was recently concluded.

**Ensartinib (X-396)**

Ensartinib (X-396) is a novel II generation, aminopyridazine-based ALK-TKI able to inhibit both wild-type ALK and all evaluated ALK variants (F1174, C1156Y, L1196M, S1206R, T1151, and G1202R mutants) with in vitro IC50 of <4 nM; it also potently inhibits TPM3-TRKA, TRKC, ROS1, EphA2, EphA1, EphB1 and c-MET (28). Preclinical data demonstrated increased potency of the drug as compared with crizotinib and other II generation TKIs (29).

Safety and efficacy were evaluated in a phase I/II trial: in the phase I part the maximum tolerated dose was not reached and the most common TRAEs were rash (56%), nausea (36%), pruritus (28%), vomiting (26%), and fatigue (22%). Differently to other II generation ALK TKIs, ensartinib induced grade 3–4 toxicity in 23% of patients mainly represented by rash and pruritus. In fact the concentration of ensartinib was 9.0 times higher in the skin than in the plasma at 12 hours after its single dose. In the phase II part 60 patients with advanced ALK-rearranged NSCLC were evaluated: the DCR was 81.7%, ORR 60% and mPFS 9.2 months. In TKI-naïve patients ORR was 80% and mPFS 26.2 months; in those progressing to crizotinib ORR was 69% and mPFS 9.0 months; in patients progressing after 2 lines of TKIs mPFS was 1.9 months (62). Twenty-six patients had at baseline brain metastasis with iORR of 69%, including 1 CR, 31% SD; DCR was 100% in patients with CNS target lesions. In those with unmeasurable lesions 1 CR was achieved and 8 pts had SD (43).

Data from the phase III trial comparing ensartinib to crizotinib, which have closed the enrollment in 2018, are awaited.

**Entrectinib (RXDX-101)**

Entrectinib is a potent, orally available, ATP competitive inhibitor of the ALK, ROS1 and TRK family rearrangements. In biochemical assay, entrectinib inhibits ALK and ROS1 with IC50 values of 12 and 7 nmol/L, respectively. In *in vitro* and *in vivo* models entrectinib showed activity against ALK-rearranged NSCLC, efficiently crossed the BBB with drug levels within the brain comparable with or exceeding plasma levels and showed a strong intracranial activity. It showed good antiproliferative activity with strong activity against G1269A mutation, slight loss of potency in presence of C1156Y and L1196M ALK-resistance mutations and minimal activity on G1202R mutant (30).

Different schedules of the drug were evaluated into 2 phase I/II trials, the Alka-372-001 trial and the
STARTTRK-1, enrolling solid tumors with rearrangements of TRK family, ROS1 or ALK. In the 2 trials 27 patients with ALK-rearranged solid tumors were present. Among the 19 patients, pretreated with 1 or more ALK TKIs, no response to entrectinib was seen. In the remaining 7 TKI-naive patients ORR was 57% (95% CI: 25–84%) and responses were observed in ALK-rearranged NSCLC, renal cell carcinoma and colorectal cancer. Median DOR in ALK population was 7.4 months (95% CI: 3.7 months–not reached) with a mPFS of 8.3 months (95% CI: 4.6–12 months); mOS wasn’t reached (95% CI: 19 months–not reached) and the proportion of patients surviving at 12 months was 89.4% (95% CI: 75.5–100%). No DLTs or significant safety issues were reported in the 2 trials with the majority AEs of only grade 1 or 2 (63-65).

Conclusions

ALK rearranged NSCLC is a relatively rare disease for which a rich amount of new targeted drugs is present with an activity, both in terms of extra and intracranial disease, stronger than that of the first in class, first generation TKI crizotinib. These drugs differ for the targeting profile, especially against resistance mutations to previous TKIs, suggesting that their use may be defined according to the biological evolution of the tumor. For this reason clarification of several molecular aspects is strongly required. Moreover they differ for the safety profile showing specific toxicity features that may influence their choice according to patient characteristics. For instance, the knowledge of these biological and clinical aspects is necessary to define the best strategy of therapeutic sequence in order to give to patients the strongest and longest response, with the best quality of life.

Acknowledgments

None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

References

14. Lovly CM, McDonald NT, Chen H, et al. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive


